FI70406C - Foerfarande foer framstaellning av farmaceutiskt aktivt karbazolyl-(4)-oxipropanolamin-derivat - Google Patents

Foerfarande foer framstaellning av farmaceutiskt aktivt karbazolyl-(4)-oxipropanolamin-derivat Download PDF

Info

Publication number
FI70406C
FI70406C FI791142A FI791142A FI70406C FI 70406 C FI70406 C FI 70406C FI 791142 A FI791142 A FI 791142A FI 791142 A FI791142 A FI 791142A FI 70406 C FI70406 C FI 70406C
Authority
FI
Finland
Prior art keywords
oxy
carbazolyl
group
propanol
formula
Prior art date
Application number
FI791142A
Other languages
English (en)
Finnish (fi)
Other versions
FI791142A (fi
FI70406B (fi
Inventor
Fritz Wiedemann
Wolfgang Kampe
Max Thiel
Gisbert Sponer
Egon Roesch
Karl Dietmann
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6036838&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI70406(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of FI791142A publication Critical patent/FI791142A/fi
Publication of FI70406B publication Critical patent/FI70406B/fi
Application granted granted Critical
Publication of FI70406C publication Critical patent/FI70406C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI791142A 1978-04-13 1979-04-06 Foerfarande foer framstaellning av farmaceutiskt aktivt karbazolyl-(4)-oxipropanolamin-derivat FI70406C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2815926 1978-04-13
DE19782815926 DE2815926A1 (de) 1978-04-13 1978-04-13 Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel

Publications (3)

Publication Number Publication Date
FI791142A FI791142A (fi) 1979-10-14
FI70406B FI70406B (fi) 1986-03-27
FI70406C true FI70406C (fi) 1986-09-19

Family

ID=6036838

Family Applications (1)

Application Number Title Priority Date Filing Date
FI791142A FI70406C (fi) 1978-04-13 1979-04-06 Foerfarande foer framstaellning av farmaceutiskt aktivt karbazolyl-(4)-oxipropanolamin-derivat

Country Status (23)

Country Link
US (1) US4503067A (ja)
EP (1) EP0004920B1 (ja)
JP (2) JPS54157558A (ja)
AT (1) AT375639B (ja)
AU (1) AU522975B2 (ja)
BG (1) BG61419B2 (ja)
CA (1) CA1129416A (ja)
CS (2) CS227007B2 (ja)
DD (1) DD143607A5 (ja)
DE (2) DE2815926A1 (ja)
DK (1) DK154555C (ja)
ES (1) ES479396A1 (ja)
FI (1) FI70406C (ja)
HK (1) HK2385A (ja)
HU (1) HU179433B (ja)
IL (1) IL57020A (ja)
LT (1) LT2628B (ja)
LU (1) LU88320I2 (ja)
MX (1) MX9203380A (ja)
NL (1) NL930110I2 (ja)
SG (1) SG52284G (ja)
SU (1) SU810079A3 (ja)
ZA (1) ZA791732B (ja)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3131146A1 (de) * 1981-08-06 1983-02-24 Boehringer Mannheim Gmbh, 6800 Mannheim Neue heteroaryloxypropanolamine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3300933A1 (de) * 1983-01-13 1984-07-19 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von d,l- und d-carazolol als antiglaukommittel sowie arzneimittel, die diese stoffe enthalten
DE3319027A1 (de) * 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
ZA938897B (en) * 1992-12-01 1994-08-01 Smithkline Beecham Corp Antioxidant neuroprotective use of and method of treatment using hydroxycarbazole compounds
US5405863A (en) * 1992-12-01 1995-04-11 Smithkline Beecham Corporation Antioxidant cardioprotective use of, and method of treatment using, hydroxycarbazole compounds
WO1994020096A1 (en) * 1993-03-05 1994-09-15 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beckman Corporation Limited Method of employing carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5308862A (en) * 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5393772A (en) * 1993-11-24 1995-02-28 Boehringer Mannheim Pharmaceuticals Corporation Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
US6177430B1 (en) 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
DE19628335A1 (de) * 1996-07-13 1998-01-15 Boehringer Mannheim Gmbh Verwendung von Carbazolyl-(4)-oxy-propanolamin-Derivaten zur topischen Behandlung von peripheren Durchblutungsstörungen
TR199900370T2 (xx) * 1996-08-23 1999-05-21 Boehringer Mannheim Pharma. Corp.-Smithkline Beecham Corp. Fas salg�lanmas�n� engelleme y�ntemi.
US5808080A (en) * 1996-09-05 1998-09-15 Eli Lilly And Company Selective β3 adrenergic agonists
ES2171839T3 (es) * 1996-09-05 2002-09-16 Lilly Co Eli Analogos de carbazol como agonistas adrenergicos selectivos de beta3.
TR199900762T2 (xx) 1996-10-09 1999-07-21 Boehringer Mannheim Pharmaceuticals Cor.Smithkline Beecham Stresle aktifle�tirilen protein kinazlar�n�n engellenme y�ntemi.
EP0893440A1 (en) * 1997-07-22 1999-01-27 Roche Diagnostics GmbH Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it
US6730326B2 (en) 1997-07-22 2004-05-04 Roche Diagnostics Gmbh Thermodynamically stable modification of 1-(4-carbazolyl-oxy-3[2-(2-methoxyphenoxy)-ethylamino]-2-propanol process for its preparation and pharmaceutical compositions containing it
ZA989365B (en) * 1997-10-15 1999-04-15 Boehringer Mannheim Pharm Corp Preparation for treating alzheimer's disease
WO1999024017A1 (en) * 1997-11-12 1999-05-20 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Bechman Corporation Limited Partnership No.1 Novel oral dosage form for carvedilol
HU227441B1 (en) * 1997-11-24 2011-06-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Process for producing carvedilol, enantiomers and salts thereof
CO5011072A1 (es) 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
DE69910188T2 (de) * 1998-04-09 2004-06-17 Roche Diagnostics Gmbh Arzneiformen enthaltend carvedilol
EP0968714A1 (de) * 1998-07-02 2000-01-05 Roche Diagnostics GmbH Verfahren zur Herstellung schnellauflösender pharmazeutischer Zubereitungen von schwerlöslichen Wirkstoffen
DE19833119A1 (de) * 1998-07-23 2000-01-27 Roche Diagnostics Gmbh Spritzfertige Injektionslösungen enthaltend Carvedilol
US6664284B2 (en) 1998-07-23 2003-12-16 Roche Diagnostics Gmbh Stabilized carvedilol injection solution
WO2000007584A2 (en) 1998-08-04 2000-02-17 Wisconsin Alumni Research Foundation Method of reducing retinal ganglion cell degeneration
PE20001302A1 (es) 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
MY125942A (en) 1999-09-07 2006-09-29 Upjohn Co Aminoalkoxy carbazoles for the treatment of cns diseases
US6515010B1 (en) 1999-11-15 2003-02-04 Smithkline Beecham Corporation Carvedilol methanesulfonate
JP2003528914A (ja) * 2000-04-03 2003-09-30 エフ．ホフマン−ラ ロシュ アーゲー カルベジロールの濃縮溶液
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
DK174645B1 (da) * 2000-05-18 2003-08-04 Gea Farmaceutisk Fabrik As Fremgangsmåde og mellemprodukter til fremstillingen af 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxy-phenoxy)-ethylamino]-propan-2-ol, carvedilol og syreadditionssalte deraf
MXPA02012795A (es) * 2000-06-28 2004-07-30 Teva Pharma Carvedilol.
EP1655285A1 (en) * 2000-06-28 2006-05-10 Teva Pharmaceutical Industries Ltd. Method for preparation of a crystalline form of carvedilol (form II)
GB0106953D0 (en) * 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
EP1385509A4 (en) * 2001-04-02 2004-06-30 Smithkline Beecham Corp TREATMENT METHOD
IN191028B (ja) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
EP1406614B1 (en) * 2001-07-13 2006-06-07 Smithkline Beecham Corporation Carvedilol polymorph
WO2003017046A2 (en) * 2001-08-14 2003-02-27 Variant Holdings, Llc. System for marketing goods and services utilizing computerized central and remote facilities
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
BR0212927A (pt) * 2001-09-28 2004-10-13 Hoffmann La Roche Formas pseudopolimórficas de carvedilol
WO2003028718A1 (en) * 2001-10-01 2003-04-10 Smithkline Beecham Corporation Novel formulations of carvedilol
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
PL371409A1 (en) * 2002-01-15 2005-06-13 Teva Pharmaceutical Industries Ltd. Crystalline solids of carvedilol and processes for their preparation
CN1649614A (zh) 2002-02-22 2005-08-03 新河药品股份有限公司 活性剂传递系统和保护及施用活性剂的方法
EP1499310A4 (en) * 2002-04-30 2005-12-07 Sb Pharmco Inc MONOCITRATE MONOHYDRATE OF CARVEDILOL
US20050261335A1 (en) * 2002-05-03 2005-11-24 Wei Chen Carvedilol formulations
AU2003231307A1 (en) * 2002-05-03 2003-11-17 Smithkline Beecham Pharmco Puerto Rico, Inc. Carvedilol pharmasolve solvate
US20050261355A1 (en) 2002-06-27 2005-11-24 Sb Pharmco Puerto Rico Inc., Carvedilol hydobromide
MXPA04012923A (es) * 2002-06-27 2005-03-31 Sb Pharmco Inc Sales de fosfato de carvedilol y/o solvatos de las mismas, composiciones correspondientes y/o metodos de tratamiento.
US20040152756A1 (en) * 2002-07-15 2004-08-05 Wei Chen Carvedilol polymorph
WO2004009120A1 (en) * 2002-07-22 2004-01-29 Nanohybrid Co., Ltd. Hybrid of itraconazole, cyclosporine or carvedilol with a layered silicate and a process for preparing the same
AP2005003232A0 (en) 2002-08-19 2005-03-31 Pfizer Prod Inc Combination therapy for hyperproliferative diseases.
US6632832B1 (en) 2002-09-10 2003-10-14 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
WO2004041252A1 (en) * 2002-11-08 2004-05-21 Egalet A/S Controlled release carvedilol compositions
SK285547B6 (sk) * 2002-11-08 2007-03-01 Zentiva, A. S. Spôsob prípravy Carvedilolu
EP1615888A1 (en) * 2003-04-21 2006-01-18 Matrix Laboratories Ltd Process for the preparation of carvedilol form-ii
JP4901474B2 (ja) * 2003-05-30 2012-03-21 ランバクシー ラボラトリーズ リミテッド 置換ピロール誘導体
US7482471B2 (en) * 2003-06-20 2009-01-27 Sun Pharmaceutical Industries Limited Process for preparation of 1-[9H-carbazol-4-yloxy]-3-[{2-(2-(-methoxy)phenoxy)-ethyl}-amino]-propan-2-ol
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
JP2007512372A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール塩、対応する組成物、送達および／または治療方法
JP2007512350A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール組成物の治療および送達方法
US20050175695A1 (en) * 2003-11-25 2005-08-11 Catherine Castan Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
US20070191456A1 (en) * 2004-04-22 2007-08-16 Tarur Venkatasubramanian R Novel process for the preparation of 1-(9h-carbazol-4-yloxy)-3-[[2-(-methoxyphenoxy)-ethyl] amino]-propan-2-ol
GB0411273D0 (en) * 2004-05-20 2004-06-23 Cipla Ltd Process and product
US20080255134A1 (en) * 2004-11-30 2008-10-16 Artesian Therapeutics, Inc. Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase
PL1838670T3 (pl) * 2004-12-09 2010-03-31 Zach System Spa Sposób wytwarzania karwedilolu i jego enancjomerów
US20070027202A1 (en) * 2005-06-07 2007-02-01 Ashok Kumar Process for the preparation of carvedilol and its salts
US20070043099A1 (en) * 2005-06-09 2007-02-22 Igor Lifshitz Crystalline forms of carvedilol and processes for their preparation
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
WO2007042912A2 (en) * 2005-10-13 2007-04-19 Orchid Research Laboratories Limited Heterocyclic compounds as pstat3/il-6 inhibitors
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
KR101329112B1 (ko) * 2005-11-08 2013-11-14 랜박시 래보러터리스 리미티드 (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
US20070238716A1 (en) * 2006-03-14 2007-10-11 Murthy Ayanampudi S R Statin stabilizing dosage formulations
US8703804B2 (en) 2006-03-26 2014-04-22 Uti Limited Partnership Ryanodine receptor inhibitors and methods relating thereto
US8022094B2 (en) * 2006-06-28 2011-09-20 Teva Pharmaceutical Industries Ltd. Carvedilol phosphate
EP2049102A4 (en) * 2006-07-14 2010-12-22 Ranbaxy Lab Ltd POLYMORPHIC FORMS OF AN HMG COA REDUCTASE HEATHER AND USE
WO2008038301A1 (en) * 2006-09-26 2008-04-03 Morepen Laboratories Limited A process for the preparation of carvedilol
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
US20090028935A1 (en) * 2006-12-01 2009-01-29 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
WO2008070072A2 (en) * 2006-12-01 2008-06-12 Mutual Pharmaceutical Company, Inc. Carvedilol forms, compositions, and methods of preparation thereof
WO2008084494A1 (en) * 2007-01-08 2008-07-17 Matrix Laboratories Limited Novel polymorphic forms of carvedilol dihydrogen phosphate and process for preparing the same
CA2930487A1 (en) * 2007-01-16 2008-07-24 Egalet Ltd. Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i)mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
CZ302357B6 (cs) * 2007-01-26 2011-03-30 Zentiva, A. S. Zpusob cištení Carvedilolu
WO2008105794A1 (en) * 2007-02-26 2008-09-04 Teva Pharmaceutical Industries Ltd. Process for the purification of carvedilol or its salts thereof
US20080249317A1 (en) * 2007-04-04 2008-10-09 Apotex Inc. Novel amorphous form of carvedilol phosphate and processes for the preparation thereof
WO2008142703A1 (en) * 2007-05-17 2008-11-27 Wanbury Limited A novel cost effective process for production of carvedilol phosphate
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
WO2009024997A1 (en) * 2007-08-21 2009-02-26 Lupin Limited Stable amorphous form of carvedilol dihydrogen phosphate with stabilizer
WO2009035535A2 (en) * 2007-09-07 2009-03-19 Scinopharm Taiwan Ltd. Method of crystallizing carvedilol phosphate and the product thereof
US20090076116A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched carvediolo
US20090111998A1 (en) * 2007-10-25 2009-04-30 Srinivas Reddy Gade Process for the preparation of carvedilol dihydrogen phosphate hemihydrate and pharmaceutical compositions thereof
EP2259801B1 (en) * 2008-03-04 2012-01-04 Lupin Limited Stable pharmaceutical compositions of carvedilol
WO2009115906A2 (en) * 2008-03-19 2009-09-24 Cadila Pharmaceuticals Ltd. An improved process for preparation of carvedilol involving halohydrin derivative
WO2009115902A1 (en) * 2008-03-19 2009-09-24 Cadila Pharmaceuticals Ltd. Process for the preparation of carvedilol via silyl protection of substituted amine
US20110015247A1 (en) * 2008-04-04 2011-01-20 Shodhana Laboratories Limited Novel crystalline form of carvedilol dihydrogen phosphate and related processes
US7763645B2 (en) * 2008-05-23 2010-07-27 Wanbury Limited Carvedilol dihydrogen phosphate monohydrate
WO2010092589A2 (en) * 2008-05-26 2010-08-19 Alkem Laboratories Ltd. Process for preparation of amorphous carvedilol phosphate
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
WO2010149169A2 (en) 2009-06-24 2010-12-29 Egalet A/S Controlled release formulations
TWI415604B (zh) 2009-09-29 2013-11-21 Tsh Biopharm Corp Ltd 調控釋放卡菲蒂羅劑型
US20110229564A1 (en) * 2010-03-22 2011-09-22 Amneal Pharmaceuticals, L.L.C. Pharmaceutical Compositions Of Carvedilol Salts And Process For Preparation Thereof
CN104080828B (zh) 2011-12-16 2016-05-04 3M创新有限公司 包含环氧乙烷的双失水己糖醇衍生物及其用途
MX2014015880A (es) 2012-07-06 2015-08-05 Egalet Ltd Composiciones farmaceuticas disuasivas de abuso para liberacion controlada.
US8492426B1 (en) * 2012-07-12 2013-07-23 Anis Ahmad Use of carvedilol for treatment of diabetes mellitus
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
US10357476B1 (en) 2018-10-30 2019-07-23 Anis Ahmad Method for treating coronary artery disease
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
CN111170997A (zh) * 2019-12-31 2020-05-19 广州医科大学 咔唑类化合物及其制备方法和应用
CN113372260A (zh) * 2021-07-05 2021-09-10 大连蒙迪科技有限公司 一种卡维地洛杂质的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1834015A (en) * 1929-06-29 1931-12-01 Gen Aniline Works Inc Manufacture of hydroxy carbazoles
DE1152107B (de) * 1956-06-27 1963-08-01 Chem Fab Promonta G M B H Verfahren zur Herstellung von basisch substituierten Carbazolderivaten und deren Salzen
US3932424A (en) * 1970-06-15 1976-01-13 Richardson-Merrell Inc. Bis-basic ethers of carbazole
BE789072A (fr) * 1971-09-23 1973-03-21 Astra Laekemedel Ab Composes abaissant le taux de lipides du serum et leur obtention
AT336176B (de) * 1971-12-10 1977-04-25 Sandoz Ag Verfahren zur herstellung eines pharmazeutischen praparates
US3975398A (en) * 1973-08-01 1976-08-17 Boehringer Mannheim G.M.B.H. 9-Substituted 3-aminocarbazole compounds
DE2339396C2 (de) * 1973-08-03 1984-06-28 Boehringer Mannheim Gmbh, 6800 Mannheim N-substituierte 1-Amino-3-phenoxypropan-2-ole, deren Salze, Verfahren zu deren Herstellung sowie Arzneimittel, die diese Verbindungen enthalten
DE2424523A1 (de) * 1974-05-21 1975-12-11 Boehringer Mannheim Gmbh Neue 1,2,3,4-tetrahydrocarbazol-derivate und verfahren zu deren herstellung
DE2454406A1 (de) * 1974-11-16 1976-05-20 Boehringer Mannheim Gmbh Neue aminopropanol-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4076829A (en) * 1974-11-16 1978-02-28 Boehringer Mannheim Gmbh Aminopropanol compounds and compositions for the treatment of cardiac and circulatory diseases
US4152446A (en) * 1974-11-16 1979-05-01 Boehringer Mannheim Gmbh Aminopropanol compounds and compositions for the treatment of cardiac and circulatory diseases
GB1508208A (en) * 1975-12-05 1978-04-19 Ici Ltd Amide derivatives
US4115409A (en) * 1975-12-05 1978-09-19 Imperial Chemical Industries Limited Alkanolamine derivatives

Also Published As

Publication number Publication date
IL57020A (en) 1982-07-30
AU522975B2 (en) 1982-07-08
JPH0123462B2 (ja) 1989-05-02
CA1129416A (en) 1982-08-10
NL930110I1 (nl) 1993-10-18
CS420091A3 (en) 1992-04-15
SG52284G (en) 1985-03-29
DK154555C (da) 1989-06-19
JPS54157558A (en) 1979-12-12
FI791142A (fi) 1979-10-14
ZA791732B (en) 1980-05-28
AU4582079A (en) 1979-10-18
US4503067A (en) 1985-03-05
CS227007B2 (en) 1984-04-16
AT375639B (de) 1984-08-27
ES479396A1 (es) 1980-04-16
FI70406B (fi) 1986-03-27
DK141979A (da) 1979-10-14
LU88320I2 (de) 1994-05-04
DE2960553D1 (en) 1981-11-05
BG61419B2 (bg) 1997-07-31
DD143607A5 (de) 1980-09-03
MX9203380A (es) 1992-09-01
DK154555B (da) 1988-11-28
HU179433B (en) 1982-10-28
LT2628B (lt) 1994-04-25
NL930110I2 (nl) 1994-12-01
EP0004920A1 (de) 1979-10-31
JPS63258416A (ja) 1988-10-25
EP0004920B1 (de) 1981-08-05
ATA276279A (de) 1984-01-15
SU810079A3 (ru) 1981-02-28
HK2385A (en) 1985-01-18
IL57020A0 (en) 1979-07-25
DE2815926A1 (de) 1979-10-18

Similar Documents

Publication Publication Date Title
FI70406C (fi) Foerfarande foer framstaellning av farmaceutiskt aktivt karbazolyl-(4)-oxipropanolamin-derivat
EP1497274B1 (fr) Derives de terphenyle, leur preparation, les compositions pharmaceutiques en contenant
EP1720848B1 (fr) Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en tant qu'inhibiteurs de l'enzyme faah
EP1641763B1 (fr) Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application comme antagonistes des recepteurs aux cannabinoides cb1
HRP930508A2 (en) Difenilpropilamina process for the preparation of the novel enylpropylamine derivatives
JPS6348864B2 (ja)
FI62054B (fi) Foerfarande foer framstaellning av farmakologiskt vaerdefulla 1-aryloxi-2-hydroxi-3-alkinylaminopropaner
JP3161892B2 (ja) インドール−７−カルボキサミド誘導体
US4363808A (en) N-(3-Phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines
EP0518939A1 (en) Antiarrhythmic agents
EP0553016A1 (fr) Nouveaux amides et sulfonamides naphtaleniques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent
US4147869A (en) 3,4-Dihydrocarbostyril derivatives and process for preparing the same
WO2001055117A1 (fr) Nouveaux derives d'isoquinoleines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JPS648621B2 (ja)
EP0333938B1 (en) 2-hydroxy-3-aryloxy-propylamine derivatives having cardiovascular activity
SK6522003A3 (en) Cyclohexyl(alkyl)-propanolamines, preparation method and pharmaceutical compositions containing same
JP3492433B2 (ja) ３−（フェニルアルキルアミノアルキルオキシ）−５−フェニルピラゾール−化合物、その製造のための方法及び中間体、及びこれを含有する心臓循環作用薬剤
US4020071A (en) Derivatives of 1-phenoxy-3-amino-propan-2-ol
US5496847A (en) Aminomethyl-benzodioxane and benzopyran serotonergic agents
EP1511728B1 (fr) Derives d oxophenyl-cyclohexyl-propanolamine, leur preparati on et leur application en therapeutique
FR2551753A2 (fr) Benzotriazine-1,2,3-ones-4, procede de preparation et medicaments les contenant
US4434174A (en) Treating cardiovascular diseases with N-(3-phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines
EP0133259A2 (en) Aminoalkyl-substituted benzene derivatives, process for production thereof, and pharmaceutical composition thereof
FR2661178A1 (fr) Derives de [(tetrahydro-1,2,3,4 isoquinoleinyl-2)methyl]-4 piperidinecarboxylates-1 d'alkyle, leur preparation et leur application en therapeutique.
KR820000199B1 (ko) 아릴-알킬아민의 제조 방법

Legal Events

Date Code Title Description
MA Patent expired
ND Supplementary protection certificate (spc) granted
SPCG Supplementary protection certificate granted

Spc suppl protection certif: L15

Extension date: 20040406

MA Patent expired

Owner name: ROCHE DIAGNOSTICS GMBH